April 24, 2018
1 min read
Save

Ten takeaways from the AACR Annual Meeting

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

This year’s American Association for Cancer Research Annual Meeting featured several potentially practice-changing studies, including many that evaluated novel immunotherapy regimens and assessed biomarkers that may predict treatment response.

HemOnc Today presents 10 updates from the meeting that may affect your practice.

  • The addition of the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who did not harbor EGFR or ALK alterations, according to results of the phase 3 KEYNOTE-189 trial. Read more.
  • Immunotherapy with nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) significantly prolonged PFS compared with standard chemotherapy among patients with newly diagnosed advanced non-small cell lung cancer with high tumor mutational burden, according to results of the randomized phase 3 CheckMate -227 trial. Read more.
  • Nivolumab continued to confer a significant OS benefit compared with investigator’s choice of therapy among patients with recurrent or metastatic head and neck squamous cell carcinoma, according to long-term data from the phase 3 CheckMate 141 trial. Read more.
  • Patients with stage III melanoma at high risk for recurrence after surgery demonstrated significantly reduced risk for recurrence after 1 year of treatment with pembrolizumab, according to results from the KEYNOTE-054/EORTC 1325. Read more.
  • Calcium channel blockers appeared associated with increased risk for pancreatic cancer among postmenopausal women. Read more.
  • The addition of abemaciclib (Eli Lilly) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the phase 3 MONARCH 3 study. Read more.
  • The addition of atezolizumab (Tecentriq, Genentech) to bevacizumab (Avastin, Genentech) plus chemotherapy extended PFS for patients with non-small cell lung cancer, according to results from the IMpower150 study. Read more.
  • The addition of the highly selective IDO1 inhibitor epacadostat (Incyte) to the PD-L1 inhibitor durvalumab (Imfinzi, AstraZeneca) appeared safe for patients with advanced solid tumors, including pancreatic cancer, melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Read more.
  • Children with nonchromosomal birth defects demonstrated significantly higher risk for certain childhood cancers. Read more.
  • The combination of pembrolizumab and CMP-001 (Checkmate Pharmaceuticals), an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition. Read more.